Executive readout · one minute
Webcast research workspace
Read the call alongside every captured source. 8-K earnings release, 10-Q stay in one workspace.
PCVX
$56.48
+0.77%
PCVX
· Vaxcyte, Inc.
$56.48
+0.43 (+0.77%)
At close · Oct 2
Return incl. dividend (before tax)
Market Cap
$8.36B
Shares
148.81M
Volume · Oct 2
2.4M
Avg daily vol (3M)
1.15M
All webcasts
Earnings call · FY2025 Q3
Vaxcyte, Inc. (PCVX) Q3 2025 Earnings Call
Forward guidance
1 guided metrics
Management's latest ranges and targets are included below.
Research coverage
2 live sources
Open each available source without leaving this research workspace.
Diluted EPS
-$1.56
Net income
-$212.83M
Research materials
Open the source you need; every reader stays inside this workspace.
Forward guidance
From the 8-K filed Nov 4, 2025.
| Metric | Period | Guided | Basis |
|---|---|---|---|
|
Capital and facility buildout expenditures (manufacturing suite)
total costs expected to be up to $350 million (buildout to be co
|
up to $350M | — |
SEC filing · Item 2.02
8-K earnings release
Filed Nov 4, 2025 · complete as-filed document
SEC periodic report
10-Q report
Filed Nov 4, 2025 · complete as-filed document